NCT02308761View on ClinicalTrials.gov

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 6, 2014

Primary Completion Date

August 9, 2017

Study Completion Date

August 9, 2017

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

RO6870810

Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.

Trial Locations (2)

10065

Weill Cornell Medical College, New York

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02308761 - A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter